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Synucleinopathies are a group of disorders characterized by the accumulation of
α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is
challenging because of the disordered nature of the protein and the stochastic nature
of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic
intervention in these pathologies. A high-throughput screening initiative allowed us
to discover ZPDm, the smallest active molecule in a library of more than 14.000
compounds. Although the ZPDm structure is highly related to that of the previously
described ZPD-2 aggregation inhibitor, we show here that their mechanisms of action
are entirely different. ZPDm inhibits the aggregation of wild-type, A30P, and H50Q α-
Synuclein variants in vitro and interferes with α-Synuclein seeded aggregation in protein
misfolding cyclic amplification assays. However, ZPDm distinctive feature is its strong
potency to dismantle preformed α-Synuclein amyloid fibrils. Studies in a Caenorhabditis
elegans model of Parkinson’s Disease, prove that these in vitro properties are translated
into a significant reduction in the accumulation of α-Synuclein inclusions in ZPDm
treated animals. Together with previous data, the present work illustrates how different
chemical groups on top of a common molecular scaffold can result in divergent but
complementary anti-amyloid activities.
Keywords: α-synuclein, protein aggregation, amyloid inhibitor, Parkinson’s disease, synucleinopathies, small
molecules
INTRODUCTION
Parkinson’s disease (PD) is an incurable disorder that affects around 0.3% of the population
and more than 1% of people over 60 years of age (4% over 80 years), being the second
most prevalent neurodegenerative disease worldwide (Nussbaum and Ellis, 2003; Dexter and
Jenner, 2013; Kalia and Lang, 2015). Together with Dementia with Lewy Bodies (DLB)
and Multiple System Atrophy (MSA), PD is part of a group of human disorders known
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as synucleinopathies (Spillantini et al., 1998a,b; Fanciulli
and Wenning, 2015). Intracellular proteinaceous inclusions
constitute the main culprit of neuronal damage and disease
progression in the synucleinopathies, although the aggregates
accumulate in different cell types and affect distinct brain regions
depending on the disease (Fellner et al., 2011; Luk et al.,
2012). These abnormal protein deposits are mostly composed
of aggregated α-synuclein (α-Syn). In the particular case of
PD, α-Syn aggregation occurs in the dopaminergic neurons of
substantia nigra pars compacta. As a consequence, PD suffering
patients display reduced dopamine levels, which results in the
archetypic motor and non-motor symptoms of the disease
(Spillantini et al., 1997). Indeed, single-point mutations and
multiplications of the gene that encodes for α-Syn (SNCA)
(Singleton et al., 2003; Ibanez et al., 2004) have been related
to familial cases of PD with early-onset (Polymeropoulos et al.,
1997), thus reinforcing the connection between α -Syn and PD.
α-Syn is an intrinsically disordered protein highly expressed
in the brain and associated with vesicle trafficking in healthy
conditions (Bendor et al., 2013). In pathological situations, α-Syn
aggregates into oligomers and amyloid fibrils that compromise
cellular homeostasis, exert toxicity and ultimately lead to
neuronal death (Serpell et al., 2000). Remarkably, diffusible
aggregated species can be internalized by healthy neighboring
neurons, where they seed the aggregation of soluble α-Syn
molecules, a mechanism that has been compared with the
templated conformational conversion occurring in prion diseases
(Hansen et al., 2011). As it occurs in prions, α-Syn assemblies
can present diverse structural arrangements, forming strains (Li
et al., 2018) that differ in their aggregation properties (Bousset
et al., 2013), and target distinct brain regions and cell types
(Lau et al., 2020).
Many of the current therapeutic approaches for PD aim to
reduce the neuronal load of aggregated α-Syn, either by targeting
the α-Syn polypeptide directly or through indirect approaches
such as the stimulation of degradation pathways (Spencer et al.,
2009; Decressac et al., 2013; Xilouri et al., 2013) and gene
silencing (Faustini et al., 2018; Kantor et al., 2018; Lassot et al.,
2018; Zharikov et al., 2019). Among them, the identification
of small compounds that might act as chemical chaperones
blocking the aggregation and propagation of α-Syn or, in the
best-case scenario, dismantling α-Syn mature aggregates into
non-toxic species is receiving increasing attention. However, the
disordered nature of α-Syn, together with the multiplicity of
conformationally different species that populate the aggregation
process, imposes significant difficulties for the rational design
of effective α-Syn binders. For this reason, high-throughput
screening (HTS) of large chemical libraries has become a
significant focus of research in the hunt for disease-modifying
lead compounds (Silva et al., 2011).
To analyze the inhibitory potential of a chemical library with
more than 14,000 chemically diverse structures, we optimized
a robust HTS screening protocol (Pujols et al., 2017) based on
Thioflavin-T (Th-T) fluorescence, light-scattering measurements
and Transmission Electron Microscopy (TEM). This pipeline
was used to discover and characterize small molecules that
act as potent inhibitors of α-Syn amyloid formation, such as
SynuClean-D (SC-D) (Pujols et al., 2018) and ZPD-2 (Pena-Diaz
et al., 2019). In the present work, we present and characterize
ZPDm (Figure 1), a novel molecule identified in the primary
HTS screen. ZPDm was the smallest compound in the library
displaying a significant inhibitory potency at a substoichiometric
concentration. ZPDm prevents the aggregation of wild type α-
Syn and the familial A30P and H50Q variants. The molecule acts
preferentially at the late stages of the polymerization reaction,
suggesting that it targets preferentially ordered aggregates.
Indeed, ZPDm is highly effective at disaggregating the mature
α-Syn fibrils of different strains. To the best of our knowledge,
it constitutes the minimal synthetic molecule that conjugates
inhibitory and α-Syn fibril disrupting activity in the same
chemical scaffold. These in vitro activities are translated into
the ability to reduce significantly α-Syn aggregation in a well-
established Caenorhabditis elegans (C. elegans) model of PD.
MATERIALS AND METHODS
Protein Expression and Purification
WT α-Syn and its variants (H50Q and A30P) were expressed and
purified as previously described (Pujols et al., 2017); the obtained
protein was lyophilised and kept at -80◦C until its use.
In vitro Aggregation of α-Syn
Lyophilised α-Syn was carefully resuspended in sterile PBS
1X and filtered through 0.22 µm membrane to discard small
aggregates. Aggregation was performed at 70 µM of α-Syn (WT,
H50Q or A30P) in a sealed 96-well plate, in a total volume of
150 µL. 40 µM Th-T in PBS 1X, a 1/8” diameter Teflon polyball
(Polysciences Europe GmbH, Eppelheim, Germany) and 100 µM
ZPDm, (trifluoromethyl)benzene or DMSO (in control samples)
FIGURE 1 | ZPDm, a ZPD-2 minimal structure. Chemical structures of (A)
2-nitro-4-(trifluoromethyl)phenyl vinyl sulfone, named ZPDm, and (B) ZPD-2,
both constituted by a hydrophobic core formed by aromatic rings and polar
projections.
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were also added to each well. The plate was incubated at 37◦C and
100 rpm fixed in an orbital shaker Max-Q 4000 (Thermo Fisher
Scientific, Waltham, Massachusetts, United States). Every 2 h, Th-
T fluorescence was measured in a Victor3.0 Multilabel Reader
(PerkinElmer, Waltham, Massachusetts, United States), exciting
through a 430–450 nm filter and collecting emission signal with a
480–510 filter. Each assay was done in triplicate and the values of





where kb and ka constitute the homogeneous nucleation
rate constant and the autocatalytic rate constant, respectively
(Crespo et al., 2016).
ZPDm was added at different concentrations in the titration
assays (200, 150, 100, 75, and 50 µM). In time-dependent assays, 7
independent aggregation reactions were prepared simultaneously
and incubated as aforementioned in a 96-well plate as triplicates.
100 µM of ZPDm were added at different time points after the
reaction had begun (4, 8, 12, 16, 20, and 24 h). In all cases α-
Syn concentration was constant at 70 µM. An equivalent volume
of DMSO was added to the control sample at the beginning
of the reaction.
For the study of the disaggregation assays, α-Syn 70 µM was
incubated in a 96-well plate as previously described for 2 days
and Th-T fluorescence measured. Then, ZPDm was added to a
final concentration of 100 µM. The plate was incubated for an
additional 24 h and Th-T fluorescence was measured.
Strains were generated as previously described (Bousset et al.,
2013; Peelaerts et al., 2015; Li et al., 2018; Carija et al., 2019).
Briefly, α-Syn was resuspended in PBS 1X and dialysed for
24 h in a 1:1,000 (v/v) ratio with either buffer B (50 mM
Tris-HCl pH 7.0) or buffer C (50 mM Tris-HCl pH 7.0, 150
mM NaCl). Dialysed samples were filtered through 0.22 µm
membranes and incubated at 70 µM for 2 days as described
above. ZPDm was added to a final concentration of 100 µM and
plates incubated for additional 24 h. Then, Th-T fluorescence
was measured.
Light-Scattering
80 µL of end-point aggregates were collected, placed
into a quartz cuvette and analyzed in a Cary Eclipse
Fluorescence Spectrophotometer (Agilent, Santa Clara, CA,
United States) by exciting at 300 and 340 nm and 90o collecting
between 280 and 360 nm.
Transmission Electron Microscopy (TEM)
End-point α-Syn aggregates were collected and Diluted 1/10 (v/v)
in PBS 1X. Diluted samples were gently sonicated for 5 min and 5
µL of the resultant sample were placed on a carbon-coated copper
grid for 5 min. Using a filter paper, the grids were dried to remove
the excess of sample and washed twice with miliQ water. Finally,
5 µL of 2% (w/v) uranyl acetate were added and left incubate for
2 min. As previously indicated, the excess of uranyl acetate was
removed, and grids were left to air-dry for 10 min. Images were
obtained using a Transmission Electron Microscopy Jeol 1400
(Peabody, MA, United States) operating at an accelerating voltage
of 120 kV. A minimum of 30 fields were screened per sample, in
order to collect representative images.
Protein Misfolding Cyclic Amplification
(PMCA)
PMCA protocol was performed as previously described (Herva
et al., 2014). Briefly, α-Syn was resuspended in Conversion
Buffer (PBS 1X, 1% Triton X-100, 150 mM NaCl) to a final
concentration of 90 µM and supplemented with Complete
Protease Inhibitor Mixture (Roche Applied Science, Penzberg,
Germany). 60 µL of this solution were loaded into 200 µL
PCR tubes containing 1.0 mm silica beads (Biospec Products,
Bartlesville, OK, United States). α-Syn was then exposed to 24 h
cycles of 30 s sonication and 30 min of incubation at 37◦C, using
a Misonix 4000 sonicator, at 70% power. The incubated sample
was recovered after each 24 h cycle and 1 µL was added to a new
PCR tube containing fresh α-Syn at 90 µM. In the case of ZPDm
treated samples, the compound was added to the fresh sample in
each step to a final concentration of 128 µM, which corresponds
to the 0.7:1 α-Syn:ZPDm ratio of the previous aggregation assays.
Untreated samples were prepared adding the same concentration
of DMSO (0.26%) present in the treated mixtures. This process
was repeated for 5 days. All the reactions were made in triplicate.
Ten microliter of aggregated samples at the end of each
cycle were diluted 1:10 with 90 µL of PBS 1X, 40 µM Th-
T. Th-T fluorescence emission was measured in a Cary Eclipse
Fluorescence Spectrophotometer (Agilent, Santa Clara, CA,
United States), by exciting the samples at 445 nm and collecting
the emission signal between 460 and 600 nm.
Proteinase K Digestion
18 µL of PMCA-aggregated α-Syn were incubated with 6 µL of
Proteinase K (5 µg/mL as final concentration) for 30 min at 37◦C.
Then, 8 µL of loading buffer containing 1% β-mercaptoethanol
was added and the sample was incubated 10 min at 95◦C for
PK inactivation. Finally, 7 µL of the samples were loaded into
a Tricine-SDS-PAGE gel. Unstained Protein Standard markers
(Thermo Fisher Scientific, Waltham, MA, United States) were
used as a reference. Gels were stained with Blue safe.
Nuclear Magnetic Resonance (NMR)
15N-labeled human WT α-Syn was expressed in E. coli BL21
DE3 strains. Cells were grown in LB medium until the optical
density (OD) at 600 nm reached a level of 0.6. Cultures were
then centrifuged at 3,000 rpm for 15 min and the obtained
pellets resuspended in 1 L of minimal medium: 768 mL of miliQ
water with 1 mL of ampicillin 100 mg/mL, 100 µL CaCl2 1M,
2 mL MgSO4 2 M, 20 mL glucose 20%, 10 mL vitamins 100x
(Sigma-Aldrich, Darmstadt, Germany), 200 mL salts M9 and
1 g 15NH4 (Cambridge Isotope Laboratories, Inc., Tewksbury,
MA, United States). Cells were incubated for 1 h at 250 rpm
and 37◦C. Finally, 1 mM IPTG was added to induce protein
expression for 4 h. Protein was purified as previously described
(Pujols et al., 2017).
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Caenorhabditis Elegans Assays
Maintenance
Animals synchronization was carried out by bleaching and
overnight hatching in M9 (3 g/L KH2PO4, 6 g/L Na2HPO4,
5 g/L NaCl, 1 M MgSO4) buffer. Thus, nematodes were cultured
at 20◦C on growth media plates (NGM) containing 1 mM
CaCl2, 1 mM MgSO4, 5 µg/mL cholesterol, 250 M KH2PO4
pH 6.0, 17 g/L Agar, 3 g/L NaCl. Plates were previously seeded
with E. coli OP50 strain. Nematodes were maintained using
standard protocols (Brenner, 1974).
Strains
Strain NL5901, unc-119(ed3) III; pkIs2386 [Punc-54::α-SYN::YFP;
unc-119(+)] was obtained from the C. elegans Genetic Center
(CGC). For the α-Syn induced dopaminergic degeneration
analysis, strain UA196 (Harrington et al., 2012), gifted generously
by the laboratory of Dr. Guy Caldwell (Department of
Biological Science, The University of Alabama, Tuscaloosa,
United States), was used; [sid-1(pk3321]; baIn33 [Pdat-1::sid-1,
Pmyo-2::mCherry]; baIn11 [Pdat-1::α-SYN; Pdat-1::GFP]). In the
main text, this strain was named Pdat-1::GFP; Pdat-1::α -SYN.
ZPDm Administration
After cooling, the autoclaved NGM agar medium (1 mM CaCl2,
1 mM MgSO4, 5 µg/mL cholesterol, 250 M KH2PO4 pH 6.0,
17 g/L Agar, 3 g/L NaCl) was enriched with 100 µM of a stock
solution of 4 mM ZPDm in 0.2% DMSO to a final concentration
of 10 µM. After 2 days, plates were seeded with 250 µL of
E. coli OP50 with 10 µM of ZPDm. Nematodes were placed
on the plates at larval stages L4 and exposed either to ZPDm
or DMSO (controls) for 7 days. Daily transfer was done to
avoid cross progeny.
Aggregate Quantification
The number of cellular inclusions was quantified as previously
described (van Ham et al., 2008; Munoz-Lobato et al.,
2014). Briefly, NL5901 (Punc-54::α-SYN::YFP) worms were age-
synchronized and left overnight to hatch. Nematodes in phase
L1 were cultured and grown into individual NGM plates seeded
with E. coli OP50. When animals reached L4 developmental
stage, they were transferred onto either ZPDm treated plates
or DMSO treated plates (negative control). Every day, animals
were transferred into a new plate to avoid cross contamination.
At stage L4+7, the aggregates in the anterior part of every
single animal were counted. For each experiment, thirty 7-
days old nematodes per treatment were analyzed using a
Nikon Eclipse E800 epifluorescence microscope equipped with
an Endow GFP HYQ filter cube (Chroma Technology Corp.,
Bellows Falls, Vermont United States) and each experiment was
carried out in triplicate. Inclusions could be described as discrete
bright structures, with edges distinguishable from surrounding
fluorescence. ImageJ software was used for measuring the
number of cellular aggregates considering the area dimensions.
For the quantification of α-syn aggregates in C. elegans one
single image was taken from each animal. However, every image
contained among 30–45 stacks (1 µm) that allowed to detect
aggregates that are at different positions.
Microscopy and Imaging
Animals were placed in a 1 mM solution of sodium azide and
mounted with a coverslip on a 4% agarose pad. Animals were
visualized with a Nikon Eclipse E800 epifluorescence microscope.
The system acquires a series of frames at specific Z-axis
position (focal plane) using a Z-axis motor device. Animals were
examined at 100× magnification to examine α-Syn induced DA
cell death and at 40× to examine α-Syn apparent aggregate.
Statistical Analysis
All graphs were generated with GraphPad Prism 6.0 software
(GraphPad Software Inc., La Jolla, CA, United States). Data were
analyzed by two-way ANOVA Tukey test using SPSS software
version 20.0 (IBM Analytics, Armonk, NY, United States) and
t-test using GraphPad software version 6.0 (GraphPad Software
Inc., La Jolla, CA, United States). All data are shown as means
and standard error of mean (SEM). P < 0.05 was considered
statistically significant. In the graphs ∗, ∗∗, and ∗∗∗ indicate
p< 0.05, p< 0.01, and p< 0.001, respectively.
RESULTS
ZPDm Inhibits α-Synuclein Aggregation
in vitro
ZPDm is a molecule that was initially identified as a positive
hit in the HTS performed by our lab back in 2017 on top of
the HitFinderTM chemical library from Maybridge (Pujols et al.,
2017). Although they were found independently, structurally,
ZPDm is a minimalistic version of ZPD-2 (Pena-Diaz et al., 2019)
with a reduced MW, LogP, and TPSA, which, in principle, would
increase its drug-likeness (Figure 1 and Table 1). Still, ZPDm
implements the generic physicochemical properties common to
most of the published inhibitors of α-Syn aggregation, namely,
a planar hydrophobic core formed by aromatic rings that
interact with apolar exposed regions in α-syn assemblies. This
core is frequently coated with polar projections that interfere
with hydrophobic packing and disrupt intermolecular hydrogen
TABLE 1 | SwissADME predicted properties of ZPDm and ZPD-2.
ZPDm ZPD-2
Molecular weight (g/mol) 281.21 424.4
Heavy atoms 18 29
Aromatic heavy atoms 6 12
H-bond acceptors 7 8
H-bond donors 0 1
TPSA (Å2) 88.34 140.66
Log PO/W 2.42 3.9
Solubility (mg/mL) 9.28E-02 1.94E-03
GI absorption High Low
Drug-like (Lipinski) 0 violations 0 violations
Drug-like (Veber) 0 violations 1 violations
Drug-like (Egan) 0 violations 2 violations
Leadlikeness 0 violations 2 violations
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bonds; they difficult elongation and, eventually, might promote
fibril disassembly (Pujols et al., 2020). A benzene ring constitutes
the hydrophobic moiety of ZPDm, connected to three polar
groups—vinyl sulfone, nitro, and trifluoromethyl – in carbon
positions 1, 2, and 4, respectively. Remarkably, the ZPD-
2 chemical structure displays the same functional groups in
carbons 1, 2, and 4 of the primary phenyl ring. However, the
vinyl sulfone is substituted by a sulfide group that extends the
molecule to incorporate additional aromatic moieties, which we
previously assumed to be critical for its activity (Pena-Diaz et al.,
2020). Thus, ZPDm can be considered as a building block for
the synthesis of the more complex ZPD-2 molecule. Considering
these structural differences, we performed a set of orthogonal
experiments to contrast if, as ZPD-2, ZPDm might turn to be a
lead compound with significant α-Syn anti-aggregational activity.
The incubation of 70 µM α-Syn with 100 µM ZPDm
inhibited the protein aggregation, decreasing the final Th-
T fluorescence signal by 60% compared to control untreated
samples (Figure 2A). Fitting of the kinetic data to a typical
sigmoidal nucleation-polymerization reaction revealed that
ZPDm diminishes the primary nucleation rate constant by
eightfold (kb = 0.0034), relative to the control reaction
FIGURE 2 | In vitro analysis of the capacity of ZPDm to inhibit α-Syn aggregation. (A) α-Syn aggregation kinetics in the absence (black) and presence (red) of 100
µM of ZPDm followed by Th-T fluorescence. (B) Light-scattering measurements at 300 and 340 nm, in the absence (white) and presence (red) of ZPDm. (C) H50Q
and A30P α-Syn variants aggregation in the absence (white) and presence (blue) of ZPDm. (D) Inhibition of α-Syn aggregation with different concentrations of ZPDm.
(E,F) Representative TEM images in the absence (E) and presence (F) of ZPDm. Th-T fluorescence is plotted as normalized means. Final points were obtained at
48 h. Error bars are represented as SE of mean values; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. ZPDm prevents the aggregation of WT, A30P, and H50Q α-Syn
variants in vitro, even at substoichiometric ratios.
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(kb = 0.0275), at the expenses of a slightly higher autocatalytic
rate constant, with ka of 0.449 and 0.323 h−1 for ZPDm
treated and untreated samples, respectively. This results in t0
and t1/2 being increased by 4 and 2 h, respectively, in the
compound’s presence. Light-scattering measurements at 300 and
340 nm at the end of the reaction reported a decrease of 81
and 78% in the dispersed light (Figure 2B) in the presence
of ZPDm, respectively, consistent with a reduction of the total
aggregated material. The visual inspection of α-Syn samples by
TEM corroborated a reduction in the number of amyloid fibrils
per field in the presence of ZPDm (Figure 2F), compared to
untreated samples (Figure 2E). A titration assay in which we
incubated 70 µM α-Syn in the presence of decreasing amounts of
ZPDm indicated a dose-dependent inhibition, with a statistically
significant activity at a substoichiometric concentration of 50
µM, at which ZPDm still reduces the Th-T signal at the end of
the reaction by 35% (Figure 2D).
We further examined if ZPDm was able to prevent the
aggregation of two mutants of α-Syn, H50Q, and A30P, which
have been associated with familial PD (Kruger et al., 1998; Appel-
Cresswell et al., 2013). The incubation of these α-Syn variants
with ZPDm reduced Th-T fluorescence at the end of the reaction
by 81 and 71% for H50Q and A30P, respectively (Figure 2C).
ZPDm, ZPD-2, and SC-D and other positive hits in
the library, share a common property, the presence of a
trifluoromethyl group connected to an aromatic ring. We
hypothesized that perhaps we were in front of the minimal
inhibitory unit, which might be very useful for future Structure
Activity Relationship (SAR) studies. Therefore, we synthesized
the (trifluoromethyl)benzene moiety and assessed its anti-
aggregational potential (Supplementary Figure S1). Both kinetic
data using Th-T and light scattering measurements converged to
indicate that this molecule is devoid of any activity, suggesting
that it might be necessary, but not sufficient to endorse ZPDm
with the above-described anti-aggregation properties.
ZPDm Prevents α-Syn Aggregation in
Protein Misfolding Cyclic Amplification
Assays
We used protein-misfolding cyclic amplification (PMCA) to
test the inhibitory capacity of ZPDm under continuous seeding
conditions. Based on the nucleation-dependent polymerization
model for prion replication, PMCA is a technique that forces
aggregation to happen by seeding soluble α-Syn with preformed
fibrils (Jung et al., 2017). After the first round of fibril elongation,
aggregates are sonicated and used as seeds for the second cycle of
PMCA. A representative sample from each cycle is then treated
with proteinase K (PK) and analyzed by SDS-PAGE, to evidence
fibril formation, since in contrast to soluble α-Syn, the fibrils
are significantly resistant to proteolysis. Using this protocol, PK-
resistant species could be observed already in the 1st cycle of
PMCA in untreated samples, with a maximum of PK resistance
at the 4th cycle (Figure 3A). Th-T fluorescence measurements
of the same samples indicated that this protection correlates
with the presence of amyloid-like assemblies (Figure 3C). In
contrast, in the presence of ZPDm, PK-resistant species are
FIGURE 3 | Inhibitory activity of ZPDm in PMCA assays. (A,B) Bis/Tris
SDS-PAGE gels of PMCA samples in the absence (A) and presence (B) of
ZPDm, before (–) and after (+) PK digestion. (C) Th-T fluorescence of different
PMCA cycles in samples treated (red) and untreated (white) with ZPDm. Th-T
fluorescence is plotted as normalized means. Error bars are represented as
SE of mean values; ∗∗p < 0.01 and ∗∗∗p < 0.001. ZPDm anti-aggregation
activity results in delayed formation of PK-resistant and Th-T positive amyloid
structures.
absent until the 3rd cycle, and they never reach the levels of
the control samples, although certain adaptation of misfolded α-
Syn to ZPDm seems to occur in cycles 4th and 5th (Figure 3B).
The Th-T fluorescence signal is negligible in the two first PMCA
cycles and significantly lower than that of control samples at any
considered cycle (Figure 3C).
ZPDm Exhibits Amyloid Disaggregation
Activity in vitro
ZPD-2 does not interact with soluble and monomeric α-Syn and,
therefore, is not expected to interfere with the protein’s functional
state. Nuclear Magnetic Resonance 1H-15N HSQC spectra of N15
labeled α-Syn in the presence and absence of ZPDm, indicates
that this is also the case for this smaller molecule since we
could not identify any perturbations in chemical shifts or peak
intensities in the spectra (Supplementary Figure S2).
To address the time window in which ZPDm remains active,
we set up an experiment in which a constant amount of ZPDm
was added to different aggregation reactions at different time
intervals after the reaction has begun (Figure 4A). To our
surprise, the respective Th-T signals indicated that the anti-
amyloid activity increased as the reaction progressed, which is
in stark contrast with the behavior of ZPD-2, which was mostly
active when added at the early stages of the reaction and inactive
when added at the plateau phase (Pena-Diaz et al., 2019). The
time-dependent activity profile of ZPDm can only be explained
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if this compound recognizes the Th-T positive aggregated species
and exerts an intense fibril disruption activity. To confirm this
extent, α-Syn mature fibrils were incubated for 24 h with ZPDm.
The Th-T fluorescence analysis revealed that treated samples
suffered a signal reduction of 74% (Figure 4B). This data was
supported by TEM images, which illustrated the disruption of
large fibrillar clusters into shorter fibrils or amorphous aggregates
(Figures 4C,D).
We assessed if this amyloid-disrupting activity was
independent of the conformational properties of the mature
fibrils, by aggregating α-Syn in 50 mM Tris–HCl pH 7.0 in
the absence or presence of 150 mM NaCl, which generates
two different strains, known as strain B and C, respectively
(Bousset et al., 2013; Carija et al., 2019). As shown in Figure 4,
the addition of ZPDm to the mature fibrils of these strains
promoted a significant decrease in the amount of amyloid-like
material as monitored both by Th-T fluorescence and TEM
24 h after the addition of the molecule (Figure 5). These data
suggest that in contrast to ZPD-2, insensitive to preformed
amyloid fibrils, ZPDm is endorsed with a generic and potent
disaggregation activity.
ZPDm Decreases the Formation of α-Syn
Aggregates in a C. elegans Model of PD
We decided to test if the ZPDm in vitro activity can be translated
in vivo to a simple animal model of PD. To do so, we employed
the well-described strain NL5901 of C. elegans. In this strain, α-
Syn is fused to Yellow Fluorescence Protein (YFP) and expressed
under the control of the unc-54 promoter, transgene pkIs2386
[Punc-54::α-SYN::YFP] (Hamamichi et al., 2008; van Ham et al.,
2008), generating protein inclusions in body wall muscle cells.
ZPDm was administered in the food at 10 µM final concentration
to animals at the L4 stage, and they were examined 7 days later,
9 days after hatching (L4+7). These aged worms are intended to
mimic aged PD patients. We used epifluorescence microscopy
to visualize the fluorescent aggregates. The images demonstrated
that ZPDm reduced the formation of muscular inclusions by
43% (Figure 6A), with an average of 20.2 ± 2.13 apparent α-
Syn aggregates in treated worms (Figure 6C) compared with the
35.2± 3.04 observed in control samples (Figure 6B).
DISCUSSION
The identification of small compounds that may abrogate the
process of protein aggregation in neurodegenerative disorders
is attracting increasing interest, both in academia and industry
(Pujols et al., 2020).
The lack of structural information about the intermediate
species that populate the reaction, and the intrinsically disordered
nature of many of the proteins behind these diseases, has made it
challenging to use of structure-guided drug design for amyloid
inhibitors. Only recently, the high-resolution structures of the
fibrils formed by proteins connected to different amyloidosis have
allowed the rational design of peptides that interfere with the
growth or seeding of the fibrils (Seidler et al., 2018; Saelices et al.,
2019; Sangwan et al., 2020). However, because peptides usually
display poor pharmacokinetics, which should be significantly
optimized before they become drugs, small molecules are still the
preferred option for the treatment of the diseases caused by the
aggregation of proteins within the brain.
The screening of large chemical libraries in the search for α-
Syn aggregation inhibitors has provided potent molecules like
anle138b (Wagner et al., 2013), BIOD303 (Moree et al., 2015),
SynuClean-D (Pujols et al., 2018), 582032 (Toth et al., 2019) or
the collection of compounds recently reported by Kurnik et al.
(2018). All these molecules display two or more aromatic rings in
their structures, a property that is shared by active polyphenols
like curcumin (Pandey et al., 2008), EGCG (Bieschke et al.,
2010), and baicalein (Jiang et al., 2010), repurposed inhibitors
like Fasudil (Tatenhorst et al., 2016), and LMTM (Schwab et al.,
2017) or compounds generated by rational design like NPT100-
18A (Wrasidlo et al., 2016). Usually, the aromatic rings form a
planar hydrophobic core that is thought to interact with apolar
exposed regions in α-Syn or its assemblies. However, despite the
presence of multiple aromatic groups is recurrent in natural α-
Syn aggregation inhibitors and many of the reported screening
efforts result in the identification of this kind of molecules, several
natural compounds exhibiting a single aromatic ring have been
shown to act as α-Syn aggregation modulators (Supplementary
Figure S3), including scyllo-inositol, gallic acid, dopamine,
safranal and caffeic acid (Herrera et al., 2008; Di Giovanni
et al., 2010; Liu et al., 2014; Ibrahim and McLaurin, 2016;
Save et al., 2019).
We recently used a robust high-throughput screening pipeline
to uncover molecules able to modulate α-Syn fibrillation (Pujols
et al., 2017). Among the active compounds, we searched for a
small compound bearing a single aromatic ring. We identified
ZPDm, which, interestingly enough, is a minimal version of ZPD-
2, a potent inhibitor identified in the same library (Pena-Diaz
et al., 2019), with half of its heavy aromatic atoms. This opened an
opportunity to approach a comparative SAR for these molecules.
ZPDm reduces the in vitro aggregation of WT α-Syn and the
protein’s A30P and H50Q familial variants in a 60%, or higher,
at a 0.7:1 (protein: ZPDm) ratio. This activity was orthogonally
confirmed by light-scattering and TEM. Moreover, the inhibitory
activity of ZPDm reduced the number of PK-resistant and Th-
T positive species in PMCA assays, thus interfering with α-Syn
templated seeding and/or aggregates amplification (Herva et al.,
2014). It should be explored whether adaptation of α-Syn to
ZPDm at late PMCA stages might translate in some resistance
to the molecule during aggregates propagation.
Solution NMR measurements indicated that ZPDm was not
interacting with soluble α-Syn monomers, and, therefore, it
is not expected to impact the physiological function of the
protein. Moreover, the addition of ZPDm at different time
points of the aggregation reaction suggested that ZPDm is
mainly active at the latest stages of the aggregation and indeed,
further analysis demonstrated that the molecule is capable of
disassembling mature α-Syn amyloid fibrils generated under
different solution conditions, conceptually similar to the α-
Syn strains observed in different synucleinopathies (Bousset
et al., 2013; Peelaerts et al., 2015). Importantly, these features
translate into a significant reduction in the number of
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FIGURE 4 | Disaggregational activity of ZPDm. (A) Th-T fluorescence of α-Syn end-point aggregates after the addition of ZPDm at different time points during the
aggregation kinetics. (B) Th-T fluorescence assay before and 24 h after the addition of ZPDm to mature α-Syn fibrils. (C,D) Representative TEM images in the
absence (C) and presence (D) of ZPDm. Th-T fluorescence is plotted as normalized means. Error bars are represented as SE of mean values; *p < 0.05 and
***p < 0.001. ZPDm inhibitory capacity increases with the reaction progress, indicating that the compound may interact with aggregated structures and disentangle
them.
apparent aggregates in the muscular cell wall of a C. elegans
model of PD when the compound is added in the food
at a concentration of 10 uM; whether this in vivo anti-
aggregational effect results in animal phenotypic benefits should
be further explored.
The above-described results illustrate how despite ZPD-2 and
ZPDm share a significant part of their chemical structure and
both are effective α-Syn aggregation inhibitors, their mechanism
of action differs significantly, with ZPD-2 acting preferentially at
the early stages of the fibrillation and becoming inactive once
the polymerization has advanced significantly, being devoid of
detectable fibril disrupting activity.
In contrast, ZPDm is more effective at later stages and
behaves as a robust disaggregating agent. The fact that
(trifluoromethyl)benzene is an inactive molecule indicates that
the bulk of the structure shared by ZPD-2 and ZPDm acts
as a building block and that the particular chemistry and
spatial disposition of the groups that decorate this moiety
are responsible for the different mode of action of these
compounds. For instance, the (trifluoromethyl)benzene contains
the aromatic ring common to the vast majority of small
active compounds. However, it lacks a strong hydrogen bond
donor/acceptor, which is another characteristic common to
many of these molecules (Supplementary Figure S3). Therefore,
our data suggest that these are the minimum requirements
for an active α-Syn aggregation inhibitor. The aromatic rings
would allow interactions with hydrophobic regions, and the
polar groups might disrupt the abundant short inter-strand
hydrogen bonds that contribute to the amyloid structure’s
sustainment. Indeed, despite their different size, the number
of hydrogen bonds acceptors in ZPD-2 and ZPDm is fairly
similar (Table 1). Despite speculative, the preferential affinity for
early-stage aggregates exhibited by ZPD-2 could be explained
by its extended aromatic core and higher Log PO/W , which
might facilitate interactions with exposed hydrophobic patches
in oligomers and small aggregates. In contrast, the compact
structure of ZPDm might allow targeting defined binding
pockets at the ends of amyloid fibrils, interfering with
fibril elongation, and eventually disrupting pre-formed non-
covalent interactions.
From a pharmacokinetic point of view, ZPDm is predicted to
be more soluble than ZPD-2, to exhibit a higher gastrointestinal
absorption and better drug-likeness (Table 1). ZPDm is also
predicted to be a better lead compound from a medicinal
chemistry perspective than ZPD-2 (Table 1).
To the best of our knowledge, the only other active molecule
with a single aromatic ring derived from the screening of a
large chemical library is the compound 576755 (Toth et al.,
2019), which in addition to a benzene ring, displays the
expected hydrogen bonds acceptors/donors (Supplementary
Figure S3). 576755 is a potent aggregation inhibitor that acts
at the oligomerization stage both in vitro and in cells. However,
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FIGURE 5 | Disaggregational effect of ZPDm in preformed fibrils of two different strains. (A) Strain B aggregates disaggregation in the presence (red) and absence
(white) of ZPDm as monitored by Th-T fluorescence. (B,C) Representative TEM images of untreated (B) and ZPDm treated (C) samples. (D) Strain C aggregates
disaggregation in presence (red) and absence (white) of ZPDm as monitored by Th-T fluorescence. (E,F) Representative TEM images of untreated (E) and ZPDm
treated (F) samples. Data are shown as means, and error bars are shown as the SE of means; ***p < 0.001. The disaggregational ability of ZPDm is also observed in
two morphologically different α-Syn strains.
FIGURE 6 | Inhibition of α-Syn inclusions formation in a C. elegans model. (A) Quantification of α-Syn muscle inclusions per area in NL5901 worms in the absence
(white) and presence of ZPDm (red). (B,C) Representative images of apparent α-Syn muscle aggregates obtained by epifluorescence microscopy of NL5901 worms
treated without (B) and with ZPDm (C). (Scale bars, 10 µm). Between 40 and 50 animals were analyzed per condition. Aggregates are indicated by white arrows.
Data are shown as means, and error bars are shown as the SE of means; **p < 0.01. NL5901 C. elegans strain forms visible accumulations of aggregated α-Syn
that are reduced when ZPDm is administered.
it was identified in a screening for compounds that interact
with monomeric α-Syn, and therefore, is not expected to
have fibril disrupting activity. Indeed, it did not impact fibril
transmission (Toth et al., 2019), consistent with its activity and
being complementary to that of ZPDm, a fibril anti-propagating
agent in PMCA assays.
Overall, here we describe a new small molecule with the
potential to be converted into a lead compound and, perhaps
more importantly, together with previous data, envision a way
to design minimal aromatic molecules with different α-Syn anti-
aggregational activities rationally. Because ZPD-2 and ZPDm
function on the same target but have complementary activity, it
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will be interesting to test if a combination of them can have a
synergic effect that overpasses the individual molecules’ potential.
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Supplementary Figure 1 | Inhibitory capacity of (trifluoromethyl)benzene. (A)
Chemical structures of (trifluoromethyl)benzene, (left) and ZPDm (right). (B) α-Syn
aggregation kinetics in the absence (black) and presence (green) of 100 µM of
(trifluoromethyl)benzene followed by Th-T fluorescence. (C) Light-scattering
measurements at 300 and 340 nm, in the absence (white) and presence (green) of
(trifluoromethyl)benzene.
Supplementary Figure 2 | NMR analysis of ZPDm lack ofinteraction with
monomeric α-Syn. 1H-15N HSQC NMR spectra of 15N-labeled α-Syn (70 µM) in
the presence (A) and in the absence (B) ofZPDm (100 µM). The superposition of
the two NMR spectra is shown in (C).
Supplementary Figure 3 | Chemical structures of different α-Syn aggregation
inhibitors with asingle aromatic ring. Chemical structures of (A) scyllo-inositol, (B)
gallic acid, (C) dopamine, (D) epinephrine, (E) norepinephrine, (F) thymoquinone,
(G) safranal, (H) caffeic acid, (I) ferulic acid, (J) protocathecuic acid, (K) tyrosol,
and (L) 576755.
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